Clinical trial · Interventional
Functional Imaging in the Assessment of mRCC Response to Sunitinib
Pilot Study to Evaluate the Feasibility of Functional MRI in Metastatic Renal Cell Carcinoma (mRCC) With Test--retest Repeatability and Early Response Assessment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Difficulty in recruiting suitable patients at centre
Summary
Brief summary (as posted)
The aim of this study is to assess whether functional magnetic resonance imaging (MRI) techniques are able to detect which patients with metastatic renal cell carcinoma will derive benefit from treatment with anti-angiogenic drugs early in their treatment. Early response assessment would allow selection of the most appropriate treatment option for each individual patient.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Imaging (MRI) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Metastatic renal cell carcinoma
- description
- Patients with clear cell renal cell carcinoma treated with anti-angiogenic therapies
- interventionNames
- Other: Magnetic Resonance Imaging (MRI)
Primary outcomes (1)
- measure
- To determine if functional MRI techniques are able to detect treatment-related changes in patients with metastatic renal cell carcinoma treated with sunitinib
- timeFrame
- At baseline and following one treatment cycle (expected 4 weeks) with anti-angiogenic therapy
Secondary outcomes (4)
- measure
- Repeatability of Arterial Spin Label and Diffusion Weighted MRI parameters
- timeFrame
- At baseline MRI scan
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with newly diagnosed (i.e. treatment naive) metastatic clear cell renal cell carcinoma judged by their treating physician to have the potential to derive benefit from anti-angiogenic therapy * Histopathologically confirmed clear cell renal cell carcinoma * Male or female aged 18 years or older Exclusion Criteria: * Previous medical treatment for renal cancer * Cardiac pacemaker or other contra-indication to magnetic resonance imaging * Contra-indication to intravenous Gadolinium * Pregnancy or breastfeeding
References
Publications (0)
Data not yet available